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The term omics consist of three main areas of molecular biology, such as genomics, proteomics and metabolomics.
The omics synergism recognise migraine as an ideal study model, due to its multifactorial nature. In this review, the
plainly research data featuring in this complex network are reported and analyzed, as single or multiple factor in
pathophysiology of migraine. The future of migraine biomolecular research shall be focused on networking among
these different and hierarchical disciplines. We have to look for its Ariadne’s tread, in order to see the whole
painting of migraine molecular biology.
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The omics synergism
Personalized Medicine aims to evaluate the individual
profile of the subject and according to it to proceed to a
specific therapeutic strategy.
This strategy is made possible by the shift from a hier-
archical to a holistic vision of the biological system. In the
first case the control of the biological system is generated
from the genome up to the lower hierarchical levels repre-
sented by proteomics and metabolomics; in the second
case, the interactions among these disciplines are evaluated
in a synergic way (Figure 1). This new approach is certainly
the most appropriate for the understanding of the physio-
pathology of migraine that, as a multifactorial disease, can
only be assessed through the integrated study of the omics
sciences. Nowadays, it is evident that migraine patients
react differently to given drugs, but the exact mechanism
has not yet been clarified. In this way, genomic and prote-
omic research aimed to the identification of molecular
pathways involved in drug action is of pivotal importance,
in order to focus attention of pharmacogenomics studies
on the right targets [1].Genomics
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in any medium, provided the original work is ptreatments, many genomic studies have been performed in
the last years. Due to neurological origin of migraine,
some researchers have studied receptors involved in medi-
ation of neuronal activities. Chen et al. [2] characterized
one polymorphism in GABRG2 gene encoding the GABAA
receptor gamma-2-subunit (rs211037) on a migraine case–
control population of 546 subjects. No significant correl-
ation was found. Carreno et al. [3] studied the transient
receptor potential (TRP) superfamily of non-selective cat-
ionic channels accountable of multimodal sensory and pain
perception, central and peripheral sensitization, and regula-
tion of calcium homeostasis, relevant steps of migraine
physiopathology. They carried out a migraine-control gen-
etic association study genotyping 149 SNPs covering 14
TRP genes. Consistent results were obtained for TRPV3
rs7217270 in the Migraine with aura group and TRPV1
rs222741 in the overall migraine group, suggesting the in-
volvement of the vanilloid TRPV subfamily of receptors to
the genetic susceptibility to migraine [4]. Another gene
analyzed is the calcium-activated potassium ion channel
gene (KCNN3) involved in neural excitability and in mi-
graine susceptibility. Cox et al. [5] performed a gene-wide
SNP genotyping in a high-risk genetic isolate from Norfolk
Island, characterized by high percentage of migraineurs. A
total of 85 SNPs spanning the KCNN3 gene were geno-
typed in a sub-sample of 285 related individuals. Only four
intronic SNPs displayed gene-wide significance: rs4845663,
rs7532286, rs6426929 and rs1218551, with the minor allele
in each case conferring protection against migraine
risk. Using the same population, Cox et al. [6] carried outan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Figure 1 Framework of the multiple interactions taking place in the migraine omics scenario.
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study found a significant statistical association with SNP
rs4807347 in ZNF555 gene, coding for a zing finger protein.
This result has been confirmed in unrelated cohort with
more than 500 patients affected by migraine. They also
found 4 SNPs in neurotransmitter-related genes (ADARB2,
GRM7 and HTR7 genes) suggesting an alteration in the se-
rotoninergic pathway. Maher et al., characterized the entire
X chromosome in an association study on the Norfolk
population and provides evidence for the SNP rs102834 in
the UTR of the HEPH gene, which is involved in iron
homeostasis [7,8]. Ligthart et al. [9] performed a meta-
analysis of GWA studies for migraine in six population-
based European cohorts consisting of 2446 cases and 8534
controls. A total of 32 SNPs showed marginal evidence for
association to migraine and the best result was obtained
for SNP rs9908234 in the nerve growth factor receptor -
NGFR- gene but those results were not replicated in other
cohorts. Besides, they found a modest gene-based signifi-
cant association between migraine and the rs1835740 near
the metadherin gene, but further replication studies did not
validated this association [10,11].The opioid system plays an important role in various bio-
logical functions including analgesia, drug response and
pain reduction. Menon et al. [12] studied the influence of
polymorphism in gene coding for the μ-opioid receptor
highlighting the association between the OPRM1 A118G
SNP and head pain severity in a clinical cohort of 153 fe-
male migraineurs with aura. In particular, G118 allele car-
riers were more likely to be high pain sufferers compared
to homozygous carriers of the A118 allele.
Migraine is a complex condition that may in part be re-
lated by endothelial and cerebrovascular disruption [13].
Some studies showed that supplementation of B vitamins
lowered homocysteine levels and reduced the occurrence of
migraine in women [14]. Besides, polymorphisms in genes
coding for key player enzymes in the folate metabolic path-
way have been investigated in order to define a relation
with the pathology and its treatment. The C677T variant in
the methylenetetrahydrofolate reductase (MTHFR) has
been associated with increased risk of migraine with aura
[15,16]. The C allele carrier is also related to higher reduc-
tion in homocysteine levels, severity of pain in migraine
and percentage of high migraine disability in patient
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has been adopted for the polymorphism A66G in methio-
nine synthase reductase gene (MTRR): the A allele carriers
showed a better response to B vitamin administration
[14]. Roecklein et al. [17] performed a haplotype analysis
of migraine risk and MTHFR, MTRR and methionine syn-
thase (MTR), including subjects with non-migraine head-
ache (N = 367), migraine without aura (N = 85), migraine
with aura (N = 167), and no headache (N = 1347). Haplo-
type analysis suggested an association between MTRR
haplotypes and reduced risk of migraine with aura.
Miao J et al. [18] performed a meta-analysis to determine
if polymorphisms in genes linked to the vascular system
could be related to migraine. They focused their attention
on the receptor for endothelin-1, (EDNRA) known as a po-
tent vasoconstrictor investigating the EDNRA -231G >A
SNP. Three studies were included in their meta-analysis for
a total of 440 migraineurs, 222 subjects with tension-type
headaches (TTHs) and 1323 controls. They found statis-
tical difference between migraineurs and controls with AA
genotype vs. AG+GG, suggesting a potential association
of -231G >A SNP and migraine. These data suggest that
individual SNPs will provide only a small piece of a much
larger puzzle composed by a variety of (un) know clinical
(phenotypic) information.
Gentile et al. [19] genotyped panel of SNPs involved in
triptans pharmacokinetics and pharmacody-namics in a
chronic migraine (CM) population. In particular they
studied the 30 bp VNTR in MAO A (monoamine oxidase
A) promoter, CYP 1A2 *1C and *1 F, CYP3A4 *1B and
C825T SNP in the gene coding the G protein b3 subunit
(GNB3). A significant association with CM was found for
the long allele of monoamine oxidase A 30 bp VNTR and
CYP1A2*1 F variant. The same authors performed an ana-
lysis of the association between genotypic and allelic fre-
quencies of the analyzed SNPs and the grade of response
to triptan administration: a significant correlation for
MAOA uVNTR polymorphism was found. Further strati-
fication of patients in abuser and non-abuser groups re-
vealed a significant association with triptan overuse and,
within the abusers, with drug response to the CYP1A2*1 F
variant [20].Proteomics
With the completion of the human genome project in
2002, it has become clear that organism complexity is gen-
erated more by a complex proteome than by a complex
genome.
Actually, the term “clinical proteomics” defines prote-
omic technologies employed to examine clinical samples
[21]. The available genomic data have now been trans-
lated to proteomics, making the discovery of biomarkers
increasingly feasible. With its high-throughput andunbiased approach to the analysis of variation in protein
expression patterns (actual phenotypic expression of gen-
etic variation), proteomics promises to be the most suit-
able platform for biomarker discovery. This hopefulness is
based on the increasing advances and ability of proteomic
technologies to identify thousands of proteins and pep-
tides in complex biological tissues and biofluids, such as
plasma, serum and urine [22]. In the past decade, many
novel proteomic technologies were emerged and applied
to several biological systems for the understanding of cel-
lular activities, disease development and physiological re-
sponses to therapeutic interventions and environmental
perturbations [23]. One of such emerging field is the appli-
cation of proteomic technologies to toxicological research,
which has given rise to a new area called toxicoproteomics
[24]. Drug induced toxicity represents a significant problem
in healthcare delivery, therefore the early detection of organ
toxicity may provide great benefits to patients, preventing
further onset of adverse events and complications of disease
management. Incidences of toxicity in liver, heart, brain,
kidney and other organs have been reported with the use of
different therapeutic drugs. In particular, various epidemio-
logic investigations proved that different drug types could
cause nephrotoxicity, especially in chronic patients.
In this regard, Bellei and co-authors reported two prote-
omic studies in which they analysed the urinary proteome
of medication-overuse headache (MOH) patients, in com-
parison with healthy non-abuser individuals as control,
with the purpose to identify possible differences in ex-
creted proteins induced by the excessive consumption
of antimigraine drugs, that could lead to nephrotoxicity
[25,26]. Comparing the proteomic profiles of patients and
controls, they found a significantly different protein ex-
pression at various MW levels, especially in the NSAIDs
group, in which six proteins over-secreted from kidney
were strongly correlated with various forms of kidney
disorders: uromodulin (UROM), alpha-1-microglobulin
(AMBP), zinc-alpha-2-glycoprotein (ZAZG), cystatin C
(CYTC), Ig-kappa-chain (IGKC), and inter-alpha-tryp-
sin heavy chain H4 (ITIH4). These preliminary results
have allowed to define the urinary protein pattern of
MOH patients, that was found to be correlated to the
abused drug. While adverse effects from long-term triptans
use are unknown, the overuse of analgesics may cause well-
known unwanted events, including liver dysfunction,
gastrointestinal bleeding, addiction and renal insufficiency
[27]. Moreover, a recent review concerning the epidemi-
ology of drug-induced disorders has demonstrated that
medication overuse could lead to nephrotoxicity and poten-
tial renal damage [28]. Currently, the most pertinent appli-
cation in nephrotoxicology is the proteomic analysis of
urine. In recent years, it has proposed a broad range of
urinary enzymes and proteins as possible early biomarkers
of drug-induced nephrotoxicity [29-31].
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While the genomics and proteomics suggest a possible
mode of operation of the system, metabolomics gives the
actual representation of the system. In agreement with the
multifactorial nature of the disease, the studies conducted
to date relate to different classes of analytes. In fact, sev-
eral different mechanisms, such as neuro-inflammatory,
neurological and cerebrovascular, have so far been sug-
gested in migraine pathophysiology [32].
Whereas the presence of inflammatory processes during
migraine attacks, serum levels of different proinflammatory
molecules have been investigated. Several studies have
found elevated levels of C-Reactive Protein (CRP), a marker
of chronic low-grade inflammation, in patients with mi-
graine [33,34]. Also the procalcitonin levels were investi-
gated as indicators of inflammation in migraine patients
with and without aura. Turan et al. found significantly high
levels of PCT in patients with migraine during the attack
compared to the interictal period (0.0485 vs 0.0298 ng/ml)
[35]. An interesting fact was found by Guldiken et al. about
the increase of soluble CD40 ligand (sCD40L). In this study,
sCD40L amount was higher in the subgroup of migraineurs
with aura than in those without aura and in rare attacks ra-
ther than in the frequent ones. In both comparisons the dif-
ference in the levels of sCD40L was not significant but
these data may be related to the association of migraine
with cardiovascular diseases [36].
Also the correlation between migraine and molecules of
pain was investigated. Several observation suggested a rela-
tionship between low serum levels of vitamin D and higher
incidence of chronic pain [37,38]. However, in a large
cross-sectional study, Kjaergaard et al. have found that low
level of serum vitamin D were associated with non-
migraine type of headache [39]. Further studies should be
conducted to clarify the potential association of vitamin
D and migraine pain. Brain-derived neurotrophic factor
(BDNF) is a neurotrophin associated with pain modulation
and central sensitization [40]. Fisher et al. have demon-
strated that in migraineurs, BDNF was significantly
elevated during migraine attacks (31.24 ± 9.31 ng/ml) com-
pared with headache-free periods (24.50 ± 9.17 ng/ml),
tension-type headache (20.97 ± 2.49 ng/ml) and healthy
controls (21.20 ± 5.64 ng/ml) [41]. This study, showing a
correlation between migraine and BDNF, supports the hy-
pothesis that BDNF has a role in the pathophysiology of
migraine. The results are in agreement with a pilot study
of Tanure et al. [42].
However, NMR or mass spectrometry techniques are
able to provide, with an acceptable probability, the de-
scription of the current biochemical state of an organism.
The development of proton magnetic resonance spectros-
copy (1H-MRS) has been used to assess noninvasively the
metabolic status of human brain [43]. Several studies
have employed 1H-MRS achieving numerous results formetabolites including N-acetylaspartate (NAA), as a marker
of neuronal functioning [44], choline (Cho), as a marker for
membrane turnover [45], total creatine (tCr) and lactate,
for energy metabolism [46], and myo-inositol (a glial
marker) [47]. With the exception of NAA, the results
obtained for these molecules are heterogeneous and some-
times contradictory. Indeed the levels of NAA are also in-
creased in the serum [48]. In our opinion, to date, it has
not been identified molecules that can be used as a marker
for migraine.
Undoubtedly, spectroscopy Nuclear Magnetic Reson-
ance and Mass Spectrometry represent the most powerful
and most widely used techniques for the simultaneous
analysis of different molecules, allowing together with
functional genomics and proteomics to open new roads
knowledge in the pathophysiology of migraine. We can
suppose that also the progression of the disease may be
evaluated by a therapeutic metabolite monitoring ap-
proach [49].
Conclusions
A conclusive scene of omics network in migraine patho-
physiology is still far to be sharpened. We know a lot of
genomics, but less of proteomics and metabolomics of mi-
graine. However, there are numerous scientific evidences
assigning an increasingly dominant role to external fac-
tors, environmental or behavioural, that interact with the
pathophysiology of migraine. Although genomics repre-
sents the hierarchical basis of migraine mechanism, prote-
omics and metabolomics mirror its real image. We have
to continue to study the connections among omics in
order to unsnarl the Ariadne’s tread of migraine.
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